To Hold or Not to Hold? Periprocedural Management of Glucagon-like Peptide-1 Receptor‑based Agonists (GLP‑1ra) in Patients with Diabetes and Obesity
Canadian Diabetes & Endocrinology Today · 25.05.2026 · 25-33
DOI: 10.58931/cdet.2026.4152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Diabetes & Endocrinology Today, online erschienen am 25.05.2026. Verfasst von Tayyab S. Khan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor-based agonists have transformed the care of patients with diabetes and obesity. However, case reports that have associated their use with retained gastric contents and pulmonary aspiration have raised concerns regarding their safe use in patients undergoing procedures involving deep sedation, general anesthesia, or upper endoscopy. Here we present the evidence underlying these concerns and provide an evidence-informed framework for the periprocedural management of these agents. Further research is needed to better characterize these risks and provide mitigation strategies for individuals taking them in the perioperative period.
Zitieren
APA
Khan, T. S. (2026). To Hold or Not to Hold? Periprocedural Management of Glucagon-like Peptide-1 Receptor‑based Agonists (GLP‑1ra) in Patients with Diabetes and Obesity. Canadian Diabetes & Endocrinology Today, 25-33. https://doi.org/10.58931/cdet.2026.4152
Vancouver
Khan TS. To Hold or Not to Hold? Periprocedural Management of Glucagon-like Peptide-1 Receptor‑based Agonists (GLP‑1ra) in Patients with Diabetes and Obesity. Canadian Diabetes & Endocrinology Today. 2026:25-33. doi:10.58931/cdet.2026.4152
BibTeX
@article{Khan2026,
author = {Khan, Tayyab S.},
title = {To Hold or Not to Hold? Periprocedural Management of Glucagon-like Peptide-1 Receptor‑based Agonists (GLP‑1ra) in Patients with Diabetes and Obesity},
journal = {Canadian Diabetes & Endocrinology Today},
year = {2026},
pages = {25--33},
doi = {10.58931/cdet.2026.4152}
}
EUVIMED